N/A N=14 Treatment

Meibomian Gland Dysfunction Treatment

Meibomian Gland Dysfunction · Dry Eye

Bottom Line

View on ClinicalTrials.gov: NCT04229888 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Mar 2022

Primary outcome: Primary: Dry Eye Questionnaire 5 (DEQ-5) Score — 11.8; 11.8 score on a scale — p=0.02

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: LipiFlow (Device); Light Based (Sham) Treatment (Device)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Indiana University
Primary completion: Mar 2021

Outcome Measures

Outcome	Result	p-value
PRIMARY Dry Eye Questionnaire 5 (DEQ-5) Score	11.8; 11.8	0.02 sig
SECONDARY Meibomian Gland Score	53.2; 52.6	0.07
SECONDARY Tear Break-Up Time (TBUT)	7.11; 5.62	0.66

Summary

The purpose of this study is to evaluate the effectiveness of treatments for Meibomian Gland Dysfunction.

Eligibility Criteria

Inclusion Criteria

evidence of meibomian gland obstruction in both eyes
dry eye symptoms per DEQ-5

Exclusion Criteria

active ocular infection
previous LipiFlow treatment
beginning new oral or other systemic medications within prior 3 months
beginning new or changing dosages of ocular medications within prior 3 months
previous ocular surgery, trauma, herpes, recurrent inflammation, punctal plugs in prior 3 months
habitual contact lens wear in prior 3 months
women who are pregnant or nursing

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04229888). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.